There are five FDA-approved anti-obesity medications: orlistat (which acts on the gastrointestinal tract and inhibits the absorption of fatty acids) [72], phentermine (which functions as an adrenergic agent, decreasing hunger) [73], phentermine–topiramate (which reduces the desire to eat by boosting dopamine), naltrexone–bupropion (which acts as naltrexone; which suppresses appetite, and bupropion is a dopamine and norepinephrine reuptake inhibitor) [74], liraglutide (which is an agonist of GLP-1), and semaglutide (which activates the GLP-1 receptor) [75]. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.